The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

The Manufacturers Life Insurance Company boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 27.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,437 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,314 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in KalVista Pharmaceuticals were worth $182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of KALV. nVerses Capital LLC purchased a new stake in shares of KalVista Pharmaceuticals during the second quarter valued at approximately $25,000. EntryPoint Capital LLC purchased a new position in shares of KalVista Pharmaceuticals in the first quarter valued at about $92,000. Entropy Technologies LP purchased a new position in shares of KalVista Pharmaceuticals in the first quarter valued at about $121,000. PEAK6 Investments LLC bought a new position in shares of KalVista Pharmaceuticals during the first quarter valued at about $178,000. Finally, Evoke Wealth LLC purchased a new stake in shares of KalVista Pharmaceuticals during the second quarter worth about $181,000.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $12.50 on Friday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.21 and a 1 year high of $16.88. The firm has a 50-day moving average of $11.79 and a 200 day moving average of $12.09. The company has a market cap of $527.35 million, a P/E ratio of -3.68 and a beta of 0.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. On average, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the transaction, the chief executive officer now owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $170,722.15. Following the sale, the chief executive officer now owns 242,527 shares in the company, valued at approximately $2,912,749.27. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $12.19, for a total transaction of $89,620.88. Following the transaction, the chief executive officer now owns 250,800 shares of the company’s stock, valued at $3,057,252. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,804 shares of company stock valued at $372,112 over the last ninety days. Company insiders own 12.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).